Oxytocin Treatment in Neonates and Infants With Prader-Willi Syndrome

PHASE3CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

March 10, 2020

Primary Completion Date

October 16, 2021

Study Completion Date

March 14, 2022

Conditions
Prader-Willi Syndrome
Interventions
DRUG

OT

One group will receive OT for 4 weeks, then placebo or OT for 8 weeks

DRUG

Placebo comparator

One group will receive Placebo for 4 weeks, then Placebo or OT for 8 weeks.

Trial Locations (7)

31059

Centre de réfrence Prader-Willi, Hospital of infants, Toulouse

Unknown

Cliniques Saint Luc, Brussels

Hôpital Femme Mère Enfant, Bron

Hôpital Jeanne de Flandre, Lille

Hôpital de la Timone Enfant, Marseille

Groupe Hospitalier Necker - Enfants Malades, Paris

Klinik für Kinderheilkunde II, Essen

All Listed Sponsors
collaborator

International Clinical Trials Association

OTHER

collaborator

Epidemiological and Clinical Research Information Network

OTHER

lead

University Hospital, Toulouse

OTHER

NCT04283578 - Oxytocin Treatment in Neonates and Infants With Prader-Willi Syndrome | Biotech Hunter | Biotech Hunter